C-Z3YVEpirium Bio
PGE-2 signaling, oral small molecules, tissue homeostasis
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Z3YV
C-Z3YVC-Z3YVPGE-2 signaling, oral small molecules, tissue homeostasis
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Epirium Bio states that restoring and enhancing mitochondrial biogenesis and function can have broad therapeutic benefit across diseases marked by deficits in these pathways. The company says it uncovered unique biological insights that led to a novel, previously undescribed pharmacological approach, and believes its IP-protected small-molecule platform can stimulate mitochondrial biogenesis and function, with its lead candidate already showing this effect in early human studies and initial focus on rare diseases.
SourceEpirium Bio states that it has uncovered unique insights into the biology of mitochondrial biogenesis and function and believes deficits in these pathways drive disease. The company says these findings support a novel, previously undescribed pharmacological approach using IP-protected small molecules to stimulate mitochondrial biogenesis and function, restore tissue bioenergetics, and treat multiple diseases, beginning with rare diseases.
SourceEpirium Bio presents the view that deficits in mitochondrial biogenesis and function are clinically important drivers of disease and that these deficits can be addressed with a novel, previously undescribed pharmacological approach. The company says its small-molecule platform can stimulate mitochondrial biogenesis and function, and it positions this mechanism as the basis for developing therapeutics, beginning with rare diseases and informed by earlier observations linking epicatechin-related compounds to improved mitochondrial function and density.
SourceEpirium Bio states that deficits in mitochondrial biogenesis and function are clinically important in disease and that these pathways can be treated through a novel pharmacological mechanism discovered by the company. It presents its small-molecule platform as a new class of therapeutics designed to stimulate mitochondrial biogenesis and function, and says its lead candidate has already shown the ability to trigger mitochondrial biogenesis in early human studies, with development beginning in rare diseases.
Source